Hound, you just agreed with me last week. I am stating the INSPIRE trial could require another 21 patients if the CEO has not been communicating openly to shareholders. Again, from the 10Q Quote: "After review of the six-month pilot data package, the FDA approved The INSPIRE study to expand enrollment from 12 to up to 30 patients."